Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Committee ...
Avanzanite entered an exclusive partnership with Agios in June 2025 to manage PYRUKYND commercialization across Europe European Commission will now review the CHMP's opinion, with the final ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback